Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13977960 | 0.96 | CCR1 (0.43) | ADRA2AADRA2BADRA2CCCR1HTR2A | |
| SCHEMBL14911823 | 0.85 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL23425843 | 0.82 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL5335231 | 0.80 | CCR1 (0.43) | ADRA2AADRA2BADRA2CCCR1HTR2A | |
| SCHEMBL6859088 | 0.80 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL8249471 | 0.80 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL9790156 | 0.80 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL11519907 | 0.80 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL21107868 | 0.78 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL12942913 | 0.78 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| WO-2016171181-A1 | 2-SUBSTITUTED FUSED PYRAZOLE DERIVATIVES | 大日本住友製薬株式会社 | 2016-10-27 | — | — | WO | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
| US-5077407-A | Substituted 2-[monoannelated (3,4-,4,5-, and 5,6-) pyridylalkylenesulfinyl]benzimidazoles | THE UPJOHN COMPANY (US) | 1991-12-31 | — | — | US | disclosed |
| EP-0130729-A2 | Alkylthio- and alkylsulfinyl-benzimidazole derivatives | THE UPJOHN COMPANY (US) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | ADRA2A 724/4885ADRA2B 693/4885ADRA2C 692/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | ADRA2A 607/4885ADRA2B 692/4885ADRA2C 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.